At that time, there was a large and dynamic pipeline of products. Further, at that time, the distribution of therapeutics in clinical trials across cancer types seems to correlate with the incidence of those cancer types reasonably well, suggesting that the pharmaceutical industry is appropriately matching its resources to the size of the market. The European Union did not match the private or public funding levels of the United States with regard to cancer therapeutic research and development.